Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Immunosuppression with daclizumab in liver transplant recipients with impaired kidney function: A single centre experience

M Post, J Raszeja-Wyszomirska, K Jarosz, M Wasilewicz, M Mydłowska, P Milkiewicz, M Wójcicki

Ann Transplant 2009; 14(1): 30-30 :: ID: 880306


Background: Nephrotoxicity of calcineurine inhibitors (CI) may exert a detrimental effect, particularly in liver transplant (OLTx) recipients with an already impaired kidney function. Immunosuppression with daclizumab permits delayed introduction of CI, and may be preferred in patients with kidney dysfunction. Aim: Retrospective analysis of our experience in immunosuppression with daclizumab in patients with impaired kidney function transplanted in our centre.
Material/Methods: One hundred and sixty eight patients were analyzed. Subjects who died within 10 days after OLTx due to surgical complications were excluded. Serum creatinine (Cr) >1.5 mg/dl was an indication for a protocol with daclizumab (50 mg i.v., day 0 and day 4), mycophenolate mofetil (MMF) 500 mg twice daily i.v./orally and prednisolone tapering doses from day 0 after OLTx. CI were introduced on day 4-15 after OLTx. Patients with Cr below 1.5mg/dl received immunosuppression with CI+MMF+steroids or CI+steroids. Data are presented as mean ±SD. Statistical analysis was done with Anova and paired t-test. P values <0.05 were considered significant.
Results: Fourteen patients fulfilled criterion for immunosuppression with daclizumab. Their Cr and creatinine clearance (CrCl) at OLTx were 2.85±1.22 mg/dl and 19±11 ml/min respectively. In remaining 154 patients Cr and CrCl were 0.88±0.3mg/dl and 107±82ml/min. respectively. At discharge, in daclizumab group Cr and CrCl were 0.97±0.45 mg/dl and 86±34 ml/min. (p<0.0001 for both, when compared to values at OLTx). Both Cr and CrCl at discharge were not statistically different when compared to Cr and CrCl in patients transplanted with the normal kidney function. The incidence of acute rejection was 14% in daclizumab group and 18% in the others (p=NS). Conclusions: Immunosuppression with daclizumab and delayed introduction of CI is safe and does not increase the risk of acute rejection thus offers an excellent therapeutic option in patients transplanted with impaired kidney function.

Keywords: Liver Transplantation, clinical outcome

Add Comment 0 Comments

In Press

12 Feb 2024 : Original article  

No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Li...

Ann Transplant In Press; DOI: 10.12659/AOT.942767  

21 Feb 2024 : Original article  

Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians

Ann Transplant In Press; DOI: 10.12659/AOT.943498  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358